References

European Association of Urology guidelines on non‐muscle‐invasive bladder cancer (TaT1 and carcinoma in situ)–a summary of the 2024 guidelines update

10.1016/j.eururo.2024.07.027 · 2024 · External reference

Bladder cancer

10.1016/s0140-6736(16)30512-8 · 2016 · External reference

Influence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy

10.1111/bju.16293 · 2024 · External reference

Advances in diagnosis and treatment of bladder cancer

10.1136/bmj-2023-076743 · 2024 · External reference

STAG2 as a prognostic biomarker in low‐grade non‐muscle invasive bladder cancer

10.1016/j.urolonc.2021.02.007 · 2021 · External reference

The prognostic value of FGFR3 expression in patients with T1 non‐muscle invasive bladder cancer

10.2147/cmar.s318893 · 2021 · External reference

High CDKN2A/p16 and low FGFR3 expression predict progressive potential of stage pT1 urothelial bladder carcinoma

10.1016/j.clgc.2018.01.009 · 2018 · External reference

Evaluation of fibroblast growth factor receptor 3 (FGFR3) and tumor protein P53 (TP53) as independent prognostic biomarkers in high‐grade non‐muscle invasive bladder cancer

2024 · External reference

Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non‐muscle invasive bladder cancer

10.1186/s13046-014-0068-7 · 2014 · External reference

Circulating tumor DNA analyses predict disease recurrence in non‐muscle‐invasive bladder cancer

10.3389/fonc.2021.657483 · 2021 · External reference

Urinary BLACAT1 as a non‐invasive biomarker for bladder cancer

10.1007/s11033-023-08370-z · 2023 · External reference

Identification of long non‐coding RNA MIR4435‐2HG as a prognostic biomarker in bladder cancer

10.3390/genes13081462 · 2022 · External reference

LncRNA MIR4435‐2HG drives cancer progression by modulating cell cycle regulators and mTOR signaling in stroma‐enriched subtypes of urothelial carcinoma of the bladder

10.1007/s13402-023-00826-5 · 2023 · External reference

MiR‐10a‐5p: a promising biomarker for early diagnosis and prognosis evaluation of bladder cancer

10.2147/cmar.s326732 · 2021 · External reference

Cell‐free microRNA‐214 from urine as a biomarker for non‐muscle‐invasive bladder cancer

10.4111/kju.2013.54.11.791 · 2013 · External reference

Fibroblast activation protein‐alpha and the immune landscape: unraveling T1 non‐muscle‐invasive bladder cancer progression

10.1016/j.euros.2024.06.011 · 2024 · External reference

Serum IL‐6 level is associated with clinical outcome of intravesical gemcitabine therapy in T1 non‐muscle‐invasive bladder cancer

10.1016/j.urolonc.2022.05.020 · 2022 · External reference

Preoperative aspartate transaminase/alanine transaminase ratio as a prognostic biomarker in primary non‐muscle‐invasive bladder cancer: a propensity score‐matched study

10.1186/s12894-021-00901-9 · 2021 · External reference

Serum soluble B7‐H3 is a prognostic marker for patients with non‐muscle‐invasive bladder cancer

10.1371/journal.pone.0243379 · 2020 · External reference

Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer

10.1016/j.urolonc.2019.05.019 · 2019 · External reference

High expression of spindle and kinetochore‐ associated protein 1 predicts early recurrence and progression of non‐muscle invasive bladder cancer

10.3233/cbm-181202 · 2018 · External reference

E‐cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder

2005 · External reference

Prognostic role of N‐cadherin expression in patients with non‐muscle‐invasive bladder cancer

10.1016/j.urolonc.2017.01.012 · 2017 · External reference

Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non‐muscle invasive bladder cancer

10.18632/oncotarget.8635 · 2016 · External reference

Preoperative systemic inflammation response index is an independent prognostic marker for BCG immunotherapy in patients with non‐muscle‐invasive bladder cancer

10.1002/cam4.5284 · 2023 · External reference

Predictive role of the systemic immune inflammation index for intravesical BCG response in intermediate‐ and high‐risk non‐muscle‐invasive bladder cancer

10.1159/000528740 · 2023 · External reference

Preoperative neutrophil‐lymphocyte ratio can significantly predict mortality outcomes in patients with non‐muscle invasive bladder cancer undergoing transurethral resection of bladder tumor

10.18632/oncotarget.14179 · 2017 · External reference

Combined assessment of peritumoral Th1/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high‐risk NMIBC

2019 · External reference

Centrosome amplification in bladder washing cytology specimens is a useful prognostic biomarker for non‐muscle invasive bladder cancer

10.1016/j.cancergen.2012.11.004 · 2013 · External reference

SH3BGRL3 protein as a potential prognostic biomarker for urothelial carcinoma: a novel binding partner of epidermal growth factor receptor

10.1158/1078-0432.ccr-14-3308 · 2015 · External reference

The effects of smoking on neutrophil/lymphocyte, platelet/lymphocyte ratios

2018 · External reference

Cigarette smoke containing acrolein contributes to cisplatin resistance in human bladder cancers through the regulation of HER2 pathway or FGFR3 pathway

10.1158/1535-7163.mct-21-0725 · 2022 · External reference

DNA damage and oxidative stress of tobacco smoke condensate in human bladder epithelial cells

10.1021/acs.chemrestox.2c00153 · 2022 · External reference

The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta‐analysis of incidence and mortality risks

10.1016/j.eururo.2015.06.042 · 2016 · External reference

Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non‐muscle‐invasive bladder cancer

10.1111/bju.70376 · 2026 · External reference

Proteomic profiling of non‐muscle invasive bladder cancer reveals potential biomarkers for recurrence and progression risk

10.1021/acs.jproteome.5c00486 · 2026 · External reference

Clinical validation of a multiplex urine biomarker assay for surveillance of recurrent bladder cancer

10.1158/1078-0432.ccr-26-1407 · 2026 · External reference